D.E. Shaw & Co
LXEO icon

D.E. Shaw & Co’s Lexeo Therapeutics LXEO Stock Holding History

D.E. Shaw & Co’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$92.5K Sell
19,866
-10,611
-35% -$57.4K ﹤0.01% 4652
2026
Q1 		$175K Sell
30,477
-449,728
-94% -$3.19M ﹤0.01% 4225
2025
Q4 		$4.77M Buy
480,205
+467,387
+3,646% +$4.26M ﹤0.01% 2347
2025
Q3 		$85.1K Buy
+12,818
New +$62K ﹤0.01% 4368

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

D.E. Shaw & Co's LXEO Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Lexeo Therapeutics (LXEO) stake by 35% in Q2 2026, selling an estimated $57.4K and leaving 19,866 shares worth $92.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4652.

D.E. Shaw & Co first reported a position in LXEO in Q3 2025 and has held it in 4 quarters since. The position peaked at $4.77M in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • D.E. Shaw & Co held 19,866 shares of Lexeo Therapeutics worth $92.5K as of Q2 2026.
  • D.E. Shaw & Co sold 10,611 Lexeo Therapeutics shares in Q2 2026, an estimated $57.4K.
  • Lexeo Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #4652 holding.
  • D.E. Shaw & Co first reported a position in Lexeo Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • D.E. Shaw & Co's Lexeo Therapeutics position peaked at $4.77M in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.